Thesis (Ph.D.)--University of Nevada, Reno, 2002. / Includes bibliographical references. Online version available on the World Wide Web.

Patients with classical vitiligo lose partially their protecting inherited pigment. The cause of the disease is still unknown. Despite massive epidermal oxidative / nitrative stress and signs for DNA-damage in the skin and in the plasma, these patients have no higher prevalence for sun induced non-melanoma skin cancer and increased photo-damage. Protection and DNA-repair have been attributed to a functioning up-regulated wild type p53 / p21 cascade in association with up-regulated p76 MDM2. As some patients with cutaneous melanoma develop depigmentations away from their primary tumour site post surgical excision, it became of our interest, whether this melanoma associated leucoderma (MAL) is the same as classical vitiligo. The purpose of this thesis was two-fold. In part I, we wanted to further substantiate the reasons behind the constantly up-regulated wild-type functioning p53 / p21 cascade in classical vitiligo utilising a panel of proteins with direct and / or indirect action on p53 regulation, including p21, p76MDM2, MDM4/MDM4phospho, SPARC, VEGF-A and TGF-β1. In part II, we wanted to characterize MAL and compare this peculiar leucoderma with classical vitiligo using the same protein panel and methodologies. To achieve our goals, we used in vivo FT-Raman spectroscopy, in vitro cell cultures, in vitro and in situ immuno-fluorescence labelling, Western blot, dot blot and computer modelling techniques. Our data showed distinct differences between classical vitiligo and MAL. Our results in MAL exhibited a concentration dependent protein expression gradient between the basal / suprabasl layers and the upper layers of the epidermal compartment using catalase, ONOO-, p53, p21, MDM4, p76MDM2, TGF-β1 and VEGF-A expression gradient. Moreover, we document for the first time the presence of a nitrated non-fuctional SPARC protein in classical vitiligo which is absent in MAL. Although we show in vivo considerable ROS / RNS- mediated stress in MAL and classical vitiligo documented by FT-Raman spectroscopy, Western blot and in situ immuno-fluorescence, our results prove that MAL and classical vitiligo are two distinct entities.

IKAROS est un facteur de transcription majeur dans l’hématopoïèse qui agit en recrutant à la chromatine de nombreux partenaires décisifs dans le renouvellement cellulaire et l’engagement vers des lignages spécifiques. Il est notamment requis dans les cellules lymphoïdes pour réprimer les gènes cibles de la voie de signalisation NOTCH. IKAROS est aussi important dans le développement des cellules érythroïdes dans lesquelles il facilite le passage d’une globine fœtale à adulte chez l’embryon grâce au recrutement des complexes remodeleurs de la chromatine NuRD et BAF. En condition normale, la voie de signalisation NOTCH réprime la différenciation en cellules érythroïdes. Il est donc important que les gènes cibles de la voie NOTCH soient finement régulés afin d’amener une cellule progénitrice à se différencier en érythrocyte énucléé. Dans les cellules hématopoïétiques, incluant les cellules érythroïdes, IKAROS est un régulateur important du gène Hes1, cible effectrice majeure de la voie NOTCH. En effet, IKAROS participe activement à la répression du gène Hes1, permettant le développement des cellules érythroïdes. Nous avons donc émis l’hypothèse que dans ces cellules, IKAROS pourrait avoir une action plus généralisée sur le contrôle des gènes ciblés par NOTCH, comme observé dans les cellules lymphoïdes. Il pourrait ainsi agir en recrutant les complexes enzymatiques nécessaires à la régulation de ces gènes comme NuRD et BAF afin d’assurer le développement des cellules érythroïdes. Étant donné que la régulation des gènes est aussi dépendante du motif de méthylation de l’ADN, nous avons étendu notre questionnement à cet autre aspect de la régulation qu’IKAROS pourrait utiliser pour contrôler les gènes de la voie NOTCH. Pour ce faire, nous avons procédé à l’analyse bio-informatique d’un séquençage d’ARN de cellules érythroïdes murines préalablement réalisé au laboratoire afin d’en extraire les gènes régulés par IKAROS, mais aussi par NOTCH. L’analyse nous a permis d’extraire deux motifs d’expression intéressants observés dans les cellules érythroïdes pour lesquels IKAROS réprime ou active des gènes qui sont normalement réceptifs à l’activation de la voie NOTCH. Parmi les gènes réprimés par IKAROS en sont ressortis les gènes cibles de NOTCH Cdkn1a (P21WAF1/CIP1) et Trp53 (TP53), dont l’expression augmente fortement quand IKAROS est muté et que NOTCH est actif. Parmi les gènes activés par IKAROS en sont ressortis les gènes cibles de NOTCH Prdm16 et Nrarp, dont l’expression diminue fortement quand IKAROS est muté et que NOTCH est actif. IKAROS est donc un régulateur pouvant être répresseur, mais aussi activateur d’une multitude de gènes ciblés par NOTCH dans les cellules érythroïdes. Par des expériences d’immunoprécipitation de la chromatine, nous avons pu observer qu’IKAROS semblait toujours agir en partenariat avec le complexe NuRD et que la présence du complexe BAF était plutôt dépendante de la voie NOTCH. L’association IKAROS-NuRD semble servir de plateforme pour imposer un état de chromatine bivalente (avec co-présence de H3K4me3 et de H3K27me3) associée à une pause transcriptionnelle. Dans ce contexte, les éléments nécessaires à l’initiation de la transcription (présence de la marque H3K4me3) des gènes ciblés par NOTCH sont recrutés mais, l’élongation transcriptionnelle est affectée. L’état de chromatine bivalente peut être associé à l’activité des déméthylases de l’ADN Ten-Eleven-Translocation (TET) qui empêchent alors l’hyperméthylation de ces régions. Nos résultats démontrent qu’IKAROS peut utiliser la protéine TET1 pour réguler des gènes cibles de la voie NOTCH, en y formant l’hydroxyméthylcytosine (5-hmC). Celle-ci peut aussi marquer les régions de régulation génique caractérisées par une chromatine bivalente et une pause transcriptionnelle. Ces travaux décrivent IKAROS comme un facteur agissant de façons multiples dans la régulation des gènes cibles de NOTCH dans les cellules érythroïdes. Nous proposons qu’IKAROS et son partenaire NuRD soient requis pour mettre en place un état de chromatine bivalente et de pause transcriptionnelle pour faciliter l’activation physiologique des gènes cibles de NOTCH lors de la signalisation. IKAROS peut ainsi prendre part à l’activation ou la répression de gènes cibles de NOTCH, tout en facilitant la déméthylation de l’ADN ainsi que le recrutement d’éléments transcriptionnels qui favorisent un état de pause transcriptionnelle. NOTCH ainsi que d’autres éléments de régulation sont alors requis pour induire l’activation ou la répression des gènes cibles. / IKAROS is a critical transcription factor in hematopoiesis. It facilitates the chromatin binding of many important co-factors required for chromatin organization during cell renewal and lineage commitment. IKAROS is particularly important in lymphoid cells whereby it is involved in the repression of target genes of the NOTCH signaling pathway. IKAROS is also important in the development of other hematopoietic lineages, including the erythroid cells, in which it facilitates the passage of a fetal to adult globin in the embryo through the recruitment of the chromatin remodeling complexes NuRD and BAF. Under normal conditions, the NOTCH signaling pathway represses development of erythroid cells. It is therefore important to precisely understand how the NOTCH target genes are regulated during passage from hematopoietic progenitor to the enucleated circulating erythrocyte. IKAROS has been demonstrated to be an important regulator of Hes1 gene expression in hematopoietic cells of different lineages. Hes1 is the major effector target of the NOTCH pathway and IKAROS actively participates in its repression. In erythroid cells, the regulation of Hes1 imposed by IKAROS is required for terminal differentiation. We therefore investigated the importance of IKAROS in the regulation of NOTCH-targeted genes in erythroid cells. The combined effect of the mutation of IKAROS with NOTCH signaling was particularly investigated in these cells. To define how IKAROS influences the regulation of NOTCH target genes, we performed the bioinformatics analysis of a RNA-sequencing performed in murine erythroid cells activated or not for NOTCH signaling and whereby IKAROS is absent. We identified genes influenced by IKAROS expression and by NOTCH, and defined the effect of the combination of the absence of IKAROS expression and NOTCH pathway activation. Two particular expression patterns were identified and characterized the combined effect of the absence of IKAROS and NOTCH pathway activation in erythroid cells. Indeed, the absence of IKAROS either favors the overexpression of NOTCH target genes or prevents their response to NOTCH pathway activation. To understand how IKAROS could have an opposite effect on different NOTCH target genes we analysed the effect of IKAROS on their regulation. Among the genes repressed by IKAROS are the target genes of NOTCH Cdkn1a (encoding the P21WAF1/CIP1 protein) and Trp53 (encoding the TP53 protein), whose expression increases strongly when IKAROS is mutated and the NOTCH pathway is activated. Prdm16 and Nrarp are, instead, requiring IKAROS expression for their activation by NOTCH. The characterization of these NOTCH target genes suggests that IKAROS can work in partnership with the NuRD complex to influence the expression. The chromatin characterization of these genes led us to posit that the IKAROS-NuRD could act as a ‘platform’ to impose a bivalent chromatin organization associated with poised transcription. Then, the regulation imposed by IKAROS-NuRD would be required for the physiological activation of NOTCH targets upon external signaling. Finally, since in embryonic stem cells the Ten-Eleven Translocation (TET) enzymes are reported to be frequently associated to bivalent chromatin in order to prevent DNA hypermethylation, we assessed whether IKAROS could interact and ‘use’ TET enzymes to regulate NOTCH target genes. We determined that IKAROS can co-immunoprecipitate with the TET1 enzymes. We show that IKAROS influences both recruitment and activity of TET1 to different NOTCH target genes and favors the accumulation of hydroxymethylcytosine (5-hmC) to these genes. 5-hmC can be considered as a mark of transcriptional pausing/bivalence. Thus, these studies bring new information on the mechanism used by IKAROS to influence gene regulation in hematopoietic cells. Our results suggest that IKAROS primary function is to organize a bivalent chromatin and to promote transcriptional pausing to multiple NOTCH target genes. IKAROS is required to set the epigenetic and promoter organization for rapid activation upon NOTCH signaling.

No description available.

Skin cancer is a prevalent disease that globally affects 2-3 million people per year [1]. This number is expected to grow tenfold as depletion of the ozone layer contributes to harsher rays reaching Earth’s surface [2]. A common way to protect against those ultraviolet waves is to apply sunscreen, however, recent reports call into question the safety of some active ingredients as they can enter through the skin into the bloodstream [3]. This thesis aims to investigate an alternative solution that uses bovine sphingomyelin (BSM) as photoprotective solution against UV irradiation. In order to evaluate the effectiveness of BSM against UV radiation, p21 intensity was measured on a monolayer of keratinocytes, as the intensity directly correlates to cell damage. Additionally, fluorescent sphingomyelin (FSM) was added as a treatment because it was created to be an analog to BSM and allowed for visualization of sphingomyelin within the cell. Differences in p21 intensities were observed with BSM and FSM showing a reduced p21 intensity compared to the no sphingomyelin case. FSM helped locate sphingomyelin within the cell and a mechanism was proposed for how it reduces cell damage. Lastly, high variation was seen between experimental designs. Further measures were needed to reduce this intra-subject standard deviation, so additional experimental parameters were tested such as min/max intensity values, cell count, and nucleus circularity to explain this variation.

The ultraviolet (UV) spectrum has been known to cause damage to skin in varying degrees. UVB radiation (290-320 nm) in particular, has been proven to be highly mutagenic and carcinogenic in many animal experiments compared to either UVA or UVC. The alarming rate of increase in skin cancer incidence has prompted many investigators to pursue other alternatives to sunscreens including changes in lifestyle habits and dietary consumption in order to boost our efforts in tackling this widespread disease. Previous studies employing confocal reflectance, MTT assay and histology suggest that milk phospholipids may possess protective properties against UVB-mediated damage but the molecular mechanism for this effect remains unclear. This study aims to evaluate changes in cell morphology, apoptosis and p21 expression in tissue engineered epidermis to increase our understanding of the mechanisms behind the potential protective effects of milk phospholipids against UV-induced photodamage. Human skin tissue equivalents were incubated in either 1% milk phospholipid solution or maintenance media then exposed to 120 mJ/cm2 dose of 300 nm UVB after 24 hours. The upregulation of p21 protein in response to DNA damage was measured with Western blot and immunofluorescence microscopy and markers for apoptosis and hyperplasia were examined 24 hours after irradiation. Results revealed that p21 levels and the amount of apoptotic markers such as fragmented DNA and nuclear condensation were significantly reduced in UV-exposed tissues pre-incubated with milk phospholipids compared to levels seen in both the positive control and UV-exposed skin tissue not incubated with milk phospholipids. This decrease in p21 expression may imply a reduction in DNA damage 24 hours after UV exposure or a decrease in acquired photodamage at the outset. Milk phospholipid incubation however, induced an increase in epidermal thickening with or without UV exposure, which may imply induction of a protective mechanism to enhance the barrier properties of skin.

Patients with classical vitiligo lose partially their protecting inherited pigment. The cause of the disease is still unknown. Despite massive epidermal oxidative / nitrative stress and signs for DNA-damage in the skin and in the plasma, these patients have no higher prevalence for sun induced non-melanoma skin cancer and increased photo-damage. Protection and DNA-repair have been attributed to a functioning up-regulated wild type p53 / p21 cascade in association with up-regulated p76 MDM2. As some patients with cutaneous melanoma develop depigmentations away from their primary tumour site post surgical excision, it became of our interest, whether this melanoma associated leucoderma (MAL) is the same as classical vitiligo. The purpose of this thesis was two-fold. In part I, we wanted to further substantiate the reasons behind the constantly up-regulated wild-type functioning p53 / p21 cascade in classical vitiligo utilising a panel of proteins with direct and / or indirect action on p53 regulation, including p21, p76MDM2, MDM4/MDM4phospho, SPARC, VEGF-A and TGF-β1. In part II, we wanted to characterize MAL and compare this peculiar leucoderma with classical vitiligo using the same protein panel and methodologies. To achieve our goals, we used in vivo FT-Raman spectroscopy, in vitro cell cultures, in vitro and in situ immuno-fluorescence labelling, Western blot, dot blot and computer modelling techniques. Our data showed distinct differences between classical vitiligo and MAL. Our results in MAL exhibited a concentration dependent protein expression gradient between the basal / suprabasl layers and the upper layers of the epidermal compartment using catalase, ONOO-, p53, p21, MDM4, p76MDM2, TGF-β1 and VEGF-A expression gradient. Moreover, we document for the first time the presence of a nitrated non-fuctional SPARC protein in classical vitiligo which is absent in MAL. Although we show in vivo considerable ROS / RNS- mediated stress in MAL and classical vitiligo documented by FT-Raman spectroscopy, Western blot and in situ immuno-fluorescence, our results prove that MAL and classical vitiligo are two distinct entities.

La stabilité de la longueur des télomères est cruciale pour le maintien de l’intégrité du génome. De nombreux problèmes peuvent survenir lors de la perte de l’intégrité des télomères, tels que le vieillissement prématuré ainsi que d’autres maladies incluant, l’insuffisance de la moelle osseuse et les cancers. Certaines cellules, telles que les cellules souches embryonnaires, expriment la télomérase permettant le maintien de la longueur des télomères. Le laboratoire Harrington a démontré que l’absence de la télomérase engendre un défaut de différenciation des mESCs à télomères courts (mESCs Tert -/-) ainsi que des perturbations épigénétiques. Ils ont aussi détecté un rétablissement de l’habilité de différenciation des mESCs Tert -/- dans le contexte d’un « knockout » de Trp53. Nous avons cherché à comprendre comment Trp53 influence la différenciation des mESCs à télomères courts en étudiant l’impact de Cdkn1a (p21) sur leur différenciation. En utilisant CRISPR/Cas9, nous avons généré plusieurs clones Cdkn1a KO afin d’analyser leur capacité à se différencier. Nous avons également étudié l’impact d’un Trp53 KO dans les mESCs Tert -/- sur les marques épigénétiques ainsi que sur la longueur des télomères. Cette étude ne nous permet pas de conclure comment p53 impact la différenciation de ces cellules, même s’il semble apparent que p21 ne soit pas directement impliqué. La poursuite de ce projet permettra de mieux comprendre le mécanisme de différenciation des mESCs et son lien avec l’intégrité des télomères et par conséquent, contribuera à mieux connaître l’impact des télomères dans le vieillissement et ses maladies associées. / Telomere length stability is crucial for the maintenance of genome integrity. Many problems can arise from a loss of telomere integrity, such as premature aging, and other diseases including anemia, bone marrow failure, and cancer. Some cells, such as embryonic stem cells, express telomerase, which allows telomere length maintenance. The Harrington group showed that the absence of telomerase generates a defect in the differentiation of ES cells with eroded telomeres (mESCs Tert -/-) and was accompanied by other epigenetic modifications. They also detected a rescue in differentiation of mESCs Tert -/- that were disrupted or knocked out (KO) for the tumor suppressor p53, encoded by Trp53. We aimed to understand how Trp53 impacts mESCs differentiation by looking at the impact of Cdkn1a (p21) on the differentiation of those cells as well as the impact of p53 KO on epigenetic marks. Using CRISPR/Cas9, we generated several p21 KO clones to analyze their ability to differentiate. We also assessed the impact of a p53 KO in mESCs Tert -/- on epigenetic marks and telomere lengths. This study does not allow us to conclude how p53 impacts differentiation of those cells, even though it appears that p21 is not directly implicated. The continuation of this project will allow a better understanding of the differentiation mechanism in mESCs and its relationship to telomere integrity, and a deeper appreciation of the impact of telomeres in aging and correlated diseases.

No description available.

No description available.